Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

In March 2022, Unlearn reached a historic milestone with the European Medicines Agency (EMA) releasing a draft qualification opinion on their 3-step PROCOVA™ procedure for Phase 2 and 3 trials. In light of this achievement, Charles Fisher, founder and CEO of Unlearn, reflects on the origin and evolution of ideas that shaped Unlearn’s groundbreaking TwinRCT™ solution—delivering on the promises methods like synthetic control arms had failed to keep of making clinical trials smaller, faster, and suitable for supporting regulatory decisions. Hear from Charles about the many twists and turns along the way as his team iterated on using digital twins in clinical trials and the journey towards their recent draft qualification opinion—proving success is never a straight line.


WHAT WILL BE COVERED IN THIS WEBINAR: 

  • Recounting the origin and evolution of ideas that shaped Unlearn’s technology from its founding through today
  • Discussing some of the early experiments that led to the development of the TwinRCT™ solution and PROCOVA™
  • Reviewing Unlearn’s recent draft qualification opinion from the EMA


WHO SHOULD ATTEND THIS WEBINAR: 

  • Academia, biotech, and pharma 
  • Biostatisticians 
  • Chief Medical Officers/Medical Directors 
  • Chief Innovation Officers/Head of Innovation 
  • Clinical Operations
  • Regulatory Affairs
  • Data Science

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Blog

Success is never a straight line—reflecting on our EMA draft qualification opinion

On March 22, 2022, we reached an historic milestone with the European Medicines Agency’s release of a draft qualification opinion on our 3-step PROCOVA™ procedure.
Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.